TLR4 and cancer: Earlier data showed that RID inhibited signaling through two inflammation-related receptors, TNFR and TLR-4, in several human cancer cell lines [15]; these observations were validated by measuring inhibition of NF-κβ signaling, JNK signaling, and chemokine secretion.